New funding to support registration of Ravidasvir DAA combination in Malaysia
The non-profit research and development organization, Drugs for Neglected Diseases initiative (DNDi) announced late last month a contribution of USD 2.2 million from Malaysian pharmaceutical company, Pharmaniaga, to support the registration of a new treatment combination for people living with the hepatitis C virus (HCV) in Malaysia.
The contribution by Pharmaniaga will support the registration of a new combination therapy using ravidasvir, which is being evaluated in combination with sofosbuvir in clinical trials in Malaysia co-sponsored by DNDi and the Malaysian Ministry of Health.
DNDi and its industrial partners will pursue registration of ravidasvir in Malaysia in 2020.
Read the press release from DnDi here: https://www.dndi.org/2019/media-centre/press-releases/efforts-register-new-hepatitisc-treatment-malaysia-support-from-pharmaniaga/
For more information, contact:
DNDi South East Asia
+60 (0)12 546 8362
mhasif [at] dndi.org
+41 22 555 19 29
+41 79 940 9017
mgibbons [at] dndi.org